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patients, the infection resolves spontaneously, whereas in others it develops into chronic disease. However, because acute
hepatitis C is often asymptomatic, detection and diagnosis are usually diﬃcult. What is more, there are no established
treatment guidelines, leaving physicians to make several challenging decisions, such as whether to treat, when to treat
and what treatment regimen to use. Pegylated interferon alfa monotherapy is most commonly used to treat patients with
acute hepatitis C; the role of ribavirin has yet to be established. In this review, we discuss the epidemiology of acute hep-
atitis C, its risk factors and routes of transmission and current treatment practices. We also discuss data from published
clinical studies and focus on unresolved issues for which additional studies are needed in order to establish standardized
treatment guidelines for the management of acute hepatitis C.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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In the past decade, the introduction of pegylated
interferons (PEG-IFNs) and the identiﬁcation of host
and viral factors that can predict sustained virological
response (SVR) have improved the treatment of chronic
hepatitis C. In contrast, because of the lack of a diagnos-
tic marker for acute hepatitis C virus (HCV) infection
and its relatively silent nature, prospective clinical inves-
tigations of acute hepatitis C have been diﬃcult to con-
duct. In this review, we attempt to synthesize existing
information on acute hepatitis C to provide a compre-
hensive overview of this condition, describe the natural0168-8278/$34.00  2008 European Association for the Study of the Liver.
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Piazza G. Cesare 11, Bari 70124, Italy.history and epidemiology of the disease and discuss
the best treatment practices.2. Epidemiology
Patients with acute HCV infection are generally
asymptomatic, which renders diagnosis diﬃcult and
results in under-reporting [1,2]. Identiﬁcation of patients
with acute hepatitis C is also hindered because many
patients are reluctant to divulge habits that may lead
to infection. As a result, estimates of the incidence vary
widely and are probably lower than the real ﬁgure. For
example, in Italy, incidence estimates range from 1 to 14
cases per 100,000, according to whether the population
evaluated included patients with acute HCV reported
to the National Surveillance Agency [3], Italian blood
donors, [4] or the general population [5]. In the United
States, the incidence of acute hepatitis C has declined
in recent years [6–8], with the Department of Health
and Human Services Center for Disease Control andPublished by Elsevier B.V. All rights reserved.
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for an overall national rate of 0.2 per 100,000. However,
after accounting for under-reporting of asymptomatic
infections, the estimated total was 20,000 new infections
[9].3. Risk factors, routes of transmission and diagnosis
Currently, intravenous drug use, unprotected sex
with multiple partners, and viral exposure during medi-
cal procedures, such as surgery, dialysis and dental
treatment, are factors associated with the highest degree
of risk for HCV infection [9–13]. Health care employees
are at risk for acute hepatitis C through accidental expo-
sure, such as needlestick injury; however, recent reports
indicate that the risk for HCV transmission after needle-
stick injury is lower than that previously believed (mean
value 0.75%; in Europe 0.42%; in Eastern Asia 1.5%)
[14]. Of note, risk factor patterns vary according to
geography. For example, within many Western coun-
tries intravenous drug use is the greatest risk factor, with
sexual transmission and medical practices representing
other less common risk factors [10,11,15]. Conversely,
in Egypt, occupational exposure seems to be the greatest
hazard, with intravenous drug use and sexual transmis-
sion less evident [16,17]. Although guidelines exist forTable 1
Relative risk for hepatitis C transmission and recommendations for testing
At-risk population Recommendations fo
High risk
Injection drug users All persons who have
have injected only on
Blood transfusion recipients or
transplantation before 1992
All patients who wer
positive for HCV
Persons who received
1992, including patie
Hemodialysis patients All patients with cur
Moderate risk
High-risk sexual activityb All sexual partners o
Vertical transmission from mother to child All children born to
Low risk
Occupational exposure All health care, emer
mucosal exposure to
Sexual activity with long-term partnersb All sexual partners o
Very low risk/no risk
Casual contact Routine testing not r
Household contact Routine testing not r
Table adapted from 2004 AASLD practice guidelines [18,19].
a Treatment guidelines recommend that patients suspected of having HCV
HCV antibodies should undergo HCV RNA testing with use of a highly se
Routine testing is recommended for patients with HIV infection and those w
b Sexual transmission of HCV is not clearly understood. However, certain h
such as anal sex, sex with trauma, sex in the presence of a sexually transmit
c Although the prevalence of infection is low, a negative test result in the pa
in clinical practice.the management of chronic hepatitis C [18,19], they do
not speciﬁcally address acute hepatitis C. Table 1 sum-
marizes recommendations for persons who are at risk
and should be tested for HCV infection.
After exposure to HCV, there is a window of 1–3
weeks before serum HCV RNA can be detected. In
patients in whom symptoms are developing, the incuba-
tion period between exposure and appearance of symp-
toms can range from 2 to 12 weeks [1]. The most
common symptoms are fatigue and jaundice, with dys-
pepsia and abdominal pain often reported [20,21]. Given
that most symptoms are non-speciﬁc, many patients do
not consult a physician and do not receive a diagnosis
during the acute phase. The ﬁrst indication of hepatic
injury is an elevated alanine aminotransferase (ALT)
level, which can occur 4–12 weeks after viral exposure
[22]. Fulminant liver injury is rare and occurs in less
than 1% of patients.
Diagnosis of acute HCV infection is conﬁrmed by the
detection of HCV RNA with documented anti-HCV
antibody seroconversion (Table 2). Seroconversion
may occur 4–10 weeks after exposure to HCV [23,24].
Other criteria that can aid in diagnosing HCV infection
include signiﬁcantly elevated ALT levels (>10 ULN or
>20 ULN), known or suspected exposure to HCV and
increasing numbers of reactive proteins in a recombi-
nant immunoblot assay conﬁrmation test [23,25].r testinga
injected illicit drugs in the recent or remote past, including those who
ce and do not consider themselves to be drug users
e notiﬁed that they received blood from a donor who later tested
transfused blood or blood products or transplanted organs before July
nts who received clotting factor concentrates before 1987
rent or previous history of hemodialysis
f HCV-infected patients
mothers infected with HCV
gency medical, and public safety workers after a needlestick injury or
HCV-positive blood
f HCV-infected patientsc
equired
equired
infection should be tested for HCV antibodies; those with detectable
nsitive assay such as reverse transcription-polymerase chain reaction.
ith unexplained elevated aminotransferase levels.
igh-risk sexual behaviors have been associated with HCV transmission,
ted disease, and sex without a condom.
rtner provides reassurance, making testing of sexual partners beneﬁcial
Table 2
Proposed criteria for diagnosis of acute hepatitis C infection
Primary criteria Presence of HCV RNA in serum of a previously
HCV-negative patient. Seroconversion from anti
HCV-negative to anti HCV-positive
Secondary criteria Elevated transaminase level P10 to 20 times the
upper limit of normal
Known or suspected exposure to HCV within the
preceding 6 months
All other causes of acute liver damage excluded
Additional
considerations
Sudden onset of liver disease
Repetition of recombinant immunoblot assay
testing to demonstrate eventual increase in the
number of reactive proteins
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An average of 26% of patients with acute hepatitis C
(range 20–67%) experience spontaneous clearance of the
virus, an event that occurs primarily during the ﬁrst 3
months after clinical onset of disease [10,11,21,26–28].
If viremia persists for more than 6 months, chronic dis-
ease should be considered. Several host and viral factors,
such as HLA, HCV genotype, co-infection with human
immunodeﬁciency virus (HIV), gender, race and
advanced age seem to inﬂuence the clinical course of dis-
ease [29], but none of these parameters can accurately
predict spontaneous resolution [2]. However, it seems
that spontaneous resolution occurs more frequently in
the presence of symptomatic disease [10,21,27,30]. Inter-
estingly, several reports have now stated that a strong
and multispeciﬁc cellular immune response is an impor-
tant host factor for spontaneous viral eradication [31–
38].
Follow-up testing of HCV RNA levels in patients
who experience spontaneous resolution is highly recom-
mended because a late relapse may occur after the initial
HCV RNA clearance [27]; therefore, HCV RNA should
be monitored for a period of at least 6 months with 2–3
consecutive tests, and subsequent testing if ALT eleva-
tion is observed. Ultimately, comparison of rates of
spontaneous viral clearance across studies of acute hep-
atitis C natural history will be possible only with the
introduction of standardized deﬁnitions and methodolo-
gies [39].Fig. 1. Sustained virological response rates among patients with acute
hepatitis C who received standard or induction doses of conventional
interferon alfa-2b (IFN alfa-2b) [40–44,46–48]. Studies of Poynard [42],
Camma` [41], and Licata [43] are meta-analyses that included at least one
study of interferon-beta. Data from Licata et al. [43] include one study of
induction therapy (Jaeckel et al. [44]) and represent the risk diﬀerence
for attaining undetectable HCV RNA versus no treatment. ALT, alanine
aminotransferase; HLB IFN, human lymphoblastoid interferon.5. Treatment of acute hepatitis C
Clinical trials focusing on the treatment of acute hep-
atitis C are hindered by the diﬃculties in its diagnosis.
Many patients who might otherwise be candidates for
treatment manifest high-risk behavior, such as ongoing
intravenous drug abuse, and are thus unsuitable for clin-
ical trials. As a result, most studies of acute hepatitis C
are open-label, non-comparative investigations withsmall patient populations that diﬀer widely with respect
to design, patient population and treatment regimens;
therefore, discerning the most eﬀective intervention
remains diﬃcult. The lack of comparative studies has
precluded the possibility that any one treatment regimen
can become a gold standard.
5.1. Conventional interferon-alfa
Treatment of acute hepatitis C patients with conven-
tional (non-pegylated) interferon (IFN) alfa has been
investigated in several small clinical trials, which typi-
cally used 3–6 million units (MU) IFN alfa administered
three times weekly for 4–24 weeks. These studies exam-
ined biochemical and virological response rates, and the
results have been summarized in several meta-analyses
(Fig. 1). Overall, 32–52% of patients treated with IFN
alfa attained SVR (deﬁned as undetectable HCV RNA
24 weeks after completing therapy) compared with only
4–11% of untreated patients [40–42]. The most recent
meta-analysis by Licata et al. [43] showed that IFN
treatment signiﬁcantly increased SVR rates (risk diﬀer-
ence, 49%; 95% CI, 32.9–65%) compared with untreated
control patients. Moreover, SVR rates increased with
higher weekly doses of IFN. Thus, higher IFN dosages
during the ﬁrst month appear to be the best treatment
option. In fact, an induction regimen of IFN alfa-2b
(5 MU/day for 4 weeks, followed by 5 MU three times
weekly for another 20 weeks) was shown to be highly
628 T. Santantonio et al. / Journal of Hepatology 49 (2008) 625–633eﬀective in treating patients with acute hepatitis C [44].
In this study, 43 of 44 (98%) patients attained SVR, with
a mean time of 3.2 weeks from initiation of treatment to
undetectable HCV RNA. Twenty-four of these patients
were followed up for a median of 135 weeks; all had
undetectable HCV RNA and no evidence of liver disease
[45].
Other studies have evaluated the eﬃcacy of early
treatment intervention with high-dose IFN alfa and
shorter treatment durations (Fig. 1). In two studies,
SVR was reported in 21 of 28 (75%) patients receiving
high-dose regimens of IFN alfa (5 MU/day) for 8 weeks
[46] and in 20 of 24 (83%) patients treated with 10 MU
IFN alfa administered daily until normalization of ALT
levels [47]. In a separate study, administration of intra-
muscular human lymphoblastoid IFN alfa (6 MU/day)
for 4 weeks resulted in SVR in 13 of 15 (87%) patients
[48]. Two patients with detectable HCV RNA at the
end of the treatment subsequently attained SVR when
treated with IFN alfa (6 MU three times weekly) for
an additional 20 weeks [48]. In addition, Nomura and
colleagues also compared the response rate achieved
with early initiation of treatment (8 weeks after diseaseTable 3
Treatment of acute hepatitis C with pegylated interferon alfa
Study Study design Treatment Therap
duratio
(wk)
Wiegand et al. [15] Open label,
uncontrolled (n = 89)
PEG-IFN alfa-2b
(1.5 lg/kg/wk)
24
De Rosa
et al. [50]
Open label,
uncontrolled (n = 19)
PEG-IFN alfa-2b
(1.06-1.66 lg/kg/wk)
12
Calleri et al. [52] Open label,
uncontrolled (n = 46)
PEG-IFN alfa-2b
(1.0-1.5 lg/kg/wk)
12
Santantonio
et al. [49]
Open label,
uncontrolled (n = 16)
PEG-IFN alfa-2b
(1.5 lg/kg/wk)
24
Broers et al. [67] Open label,
uncontrolled (n = 14)
PEG-IFN alfa-2b
(1.5 lg/kg/wk)
24
Kamal et al. [30] Randomised,
comparative (n = 40)
PEG-IFN alfadvs
PEG-IFN alfad
+ RBV (800 mg/d or
>10.6 mg/kg/d)
24
Kamal et al. [17] Randomised
comparative (n = 68e)
PEG-IFN alfa-2b
(1.5 lg/kg/week)
12
24
EOT, end-of-treatment response; IVDU, intravenous drug users; NR, not re
a Included patients who attained SVR while receiving PEG-IFN alfa-2b onc
of tolerability (n = 4).
b 70/89 (79%) patients receivedP80% of the planned dose forP80% of th
and the SVR rate was 89%.
c Treatment was initiated immediately after diagnosis.
d 24 subjects received PEG-IFN alfa-2a (180 lg/kg/wk) (n = 12 monotherap
alfa-2 b (1.5 lg/kg/wk) (n = 8 monotherapy and n = 8 combination therapy)
e Data from the 8 week treatment arm (n = 34) not presented.onset) with a delayed treatment strategy and demon-
strated that therapy initiated after one year is clearly less
eﬀective [48]. Similarly, in the meta-analysis by Licata
et al. delaying initiation of therapy until 60 days after
onset of disease did not compromise the probability of
a favorable response [43]. Overall, published data indi-
cate that acute hepatitis C can be eﬀectively managed
with early or delayed treatment (8-weeks) using a 4- to
24-week course of conventional IFN alfa.
5.2. Pegylated interferon alfa
Treatment of chronic hepatitis C has advanced with
the introduction of pegylated interferon (PEG-IFN)
alfa, which, in combination with ribavirin, has become
the current standard of care. Diﬀerent strategies have
been explored to optimize SVR rates in patients with
acute hepatitis C treated with PEG-IFN alfa-2b
(Table 3, Fig. 2). When considering treatment initiation,
several time points have been evaluated, ranging from
immediately after diagnosis to after an observation per-
iod of several weeks. In a study conducted by Wiegand
et al. [15], 89 patients were treated after a median timey
n
Time from
diagnosis/
infection to
treatment
(median)
EOT SVR Predictors
of SVR
76 days 82%a 63/89 (71%)a,b ALT >500 U/L
(P = 0.039)
31 days NR 14/19 (74%) PEG-IFN dose:
P1.33 lg/kg/wk
(P = 0.0379)
15 daysc 41/46 (89%) 33/46 (72%) PEG-IFN alfa-2b
dose
P 1.2 lg/kg/wk
(P = 0.014)
12-week
observation
period
15/16 (94%) 15/16 (94%) NR
1–50 weeks 86% 57% Active IVDU >80%
of the scheduled
drug
12-week
observation
period
18/20 (90%)
vs 19/20 (95%)
17/20 (85%)
vs 16/20 (80%)
NR
8–12 weeks 30/34 (88.2%) 28/34 (82.4%) NR
8–12 weeks 32/34 (94.1%) 31/34 (91.2%) NR
ported; SVR, sustained virological response.
e every 2 weeks (n = 1) or for a shorter period of 8 to 16 weeks because
e intended duration. In these patients, the EOT response rate was 94%
y and n = 12 combination therapy), and 16 patients received PEG-IFN
.
Fig. 2. Sustained virological response (SVR) among patients with acute
hepatitis C who received pegylated interferon alfa-2b for 12 or 24 weeks.
Data from Kamal et al. [17] were derived from separate treatment arms
in the same study.
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using the standard dosage for chronic HCV infection
(1.5 lg/kg/wk); after 24 weeks of treatment, the overall
SVR rate was 71%, but it increased to 89% in the subset
of patients receiving 80% of the scheduled dosage within
80% of the planned treatment period. The diﬀerence in
response rates between adherent and intent-to-treat
populations was attributed to the large number of
patients lost to follow-up, protocol violations, and treat-
ment failure among the patients receiving PEG-IFN
alfa-2b. Three serious adverse events, including one sui-
cide, might have been related to the study drug [15].
Immediate treatment of patients after diagnosis may
mean some patients who would have cleared the infec-
tion spontaneously will be exposed to antiviral therapy
unnecessarily and may experience treatment-related
adverse events. Therefore, treatment strategies involving
delayed therapy have also been investigated. In an early
pilot study [49], treatment was delayed for 12 weeks
after clinical presentation of the disease; patients with
detectable HCV RNA then received PEG-IFN alfa-2b
(1.5 lg/kg/wk) for 24 weeks [15]. Fifteen of 16 treated
patients (94%) attained SVR. Moreover, HCV RNA
remained undetectable up to 12 months after therapy
discontinuation [49]. Similar results were also reported
in a randomized controlled trial in which 129 patients
received 12-weeks’ treatment with PEG-IFN alfa-2b
(1.5 lg/kg/wk) after a clinical observation period of 8,
12, or 20 weeks [16]. The SVR was equivalent in patients
treated after a delay of 8 or 12 weeks (95% versus 93%)
but was signiﬁcantly lower in patients treated after a 20-
week delay (76%; P 6 0.03 for both comparisons).When results were evaluated according to HCV geno-
type, genotype 1 patients appeared to obtain greater
beneﬁt from earlier treatment initiation [16].
Regarding treatment duration, several recent trials
have evaluated the eﬃcacy of a short, 12-week course
of PEG-IFN therapy [50–52]. In these studies, most
patients were asymptomatic and many were intravenous
drug users. Patients were treated with PEG-IFN alfa-2b
(1.0–1.5 lg/kg/wk) within a median time of 13.5–31
days after peak ALT levels. SVR was attained in 72–
74% of patients, and higher rates of SVR (83–92%) were
attained by patients receiving higher PEG-IFN alfa-2b
dosages (>1.33 and >1.2 lg/kg/wk). This short course
of therapy might be particularly useful in diﬃcult-to-
treat patients, such as intravenous drug users who
typically have more frequent side eﬀects that lead to
treatment discontinuation. In the only randomized trial
conducted to date, 102 patients with acute hepatitis C
who still had detectable HCV RNA after 8–12 weeks
of observation were randomly assigned to receive
PEG-IFN alfa-2b (1.5 lg/kg/wk) for 8, 12 or 24 weeks.
Overall SVR rates were 62%, 82% and 91%, respectively.
When analyzing the results according to genotype,
patients infected with genotype 1 required a longer per-
iod of therapy (24 weeks) to maximize their likelihood of
attaining SVR [17]. Finally, on the basis of the limited
data in the literature, combination therapy with ribavi-
rin does not result in improved treatment outcomes [30].
In most studies performed to date, response rates
appear to be independent of HCV genotype, and
patients with genotype 1 have demonstrated results sim-
ilar to those of patients with genotype 2 or 3 [46,49].
Kamal et al. [16,17] reported a possible lower response
rate in genotype 1 patients, but this observation requires
conﬁrmation. In the German Acute HCV II trial, base-
line HCV RNA was not associated with treatment out-
come, but multivariate regression analysis indicated that
SVR was correlated with pretreatment ALT levels
(P = 0.039) [15]. In contrast, in the trial by Calleri
et al. [52], the peak viral load before treatment was pre-
dictive of SVR in univariate analysis (P = 0.0005); they
also found that undetectable HCV RNA at weeks 4 and
12 of treatment was predictive of SVR. These prelimin-
ary observations indicate that, as in chronic hepatitis C,
viral kinetics may become an important predictor of
treatment outcome in acute hepatitis C.
5.3. Treatment of acute hepatitis C among HIV-co-
infected patients
Co-infection with HIV seriously complicates the
management of chronic hepatitis C. Co-infected patients
experience an accelerated disease course and reduced
SVR rates when compared with mono-infected HCV
[53–55]. Evidence also suggests that HIV co-infection
can alter the disease course and treatment outcome for
630 T. Santantonio et al. / Journal of Hepatology 49 (2008) 625–633patients in the acute stages of HCV infection, but studies
are few and patient numbers are small.
Co-infection with HIV renders spontaneous resolu-
tion of HCV infection unlikely. In one study of 25
patients with acute hepatitis C and HIV, only one
(4%) attained spontaneous resolution. Most of these
patients were receiving highly active antiretroviral ther-
apy, and the median CD4+ T-cell count in this cohort
was 345 cells/ll [56]. HIV co-infection is may also exert
an unfavorable impact on treatment outcome; however,
this remains controversial, and data from several small
studies report SVR rates ranging from 0% to 71%
among co-infected patients receiving PEG-IFN alfa
alone or PEG-IFN alfa plus ribavirin for 24 weeks.
These studies indicate that no clear clinical beneﬁt is
derived by the addition of ribavirin to PEG-IFN alfa-
2b monotherapy [56–59]. These SVR rates are generally
lower than those observed in patients with acute HCV
mono-infection but are higher than those in HIV
patients with chronic HCV infection (27–40% [53–55]).
Taken together, early antiviral therapy seems to be
appropriate in co-infected patients in the absence of
contraindications to treatment.
5.4. Treatment of acute hepatitis C among hemodialysis
patients
HCV infection is common in patients with end-stage
renal disease; estimates suggest that 3–22% of patients
undergoing maintenance dialysis may have HCV infec-
tion [60]. Little is known regarding the treatment of
acute hepatitis C in this population, and only a small
number of observational studies have been published
[61–63]. In general, these studies demonstrated that
IFN alfa or PEG-IFN alfa therapy is eﬀective; each pro-
duced SVR rates of 57–86% and was well tolerated
[61,62,64,65], but further studies are required.6. Remaining questions and future directions
Recent studies have begun to address several impor-
tant questions with regard to best treatment practices
for patients with acute hepatitis C. Unfortunately, avail-
able data lack the robust quality required to develop
standardized treatment recommendations. Nevertheless,
an abundance of useful information can be drawn from
currently published data. Questions that remain unan-
swered and the current status of ongoing studies are as
follows:
1. When should therapy be initiated? Data from trials
using immediate or delayed treatment strategies (8–
12 weeks) have demonstrated high SVR rates ranging
from 71% to 94% (Fig. 2). Delaying treatment for 2–3
months after disease onset permits the identiﬁcationof patients whose infections spontaneously resolve.
Whether an immediate treatment approach is more
appropriate in patients with asymptomatic disease
or in those infected with genotype 1b still requires
conﬁrmation. The German Competence Network
for Viral Hepatitis (HEP-NET) [66] is conducting a
randomised, controlled trial comparing immediate
treatment (PEG-IFN alfa-2b 1.5 lg/kg/wk for 24
weeks) at the onset of symptoms with a delayed treat-
ment strategy in which patients undergo a 12-week
observation period, after which only those patients
who have detectable HCV RNA receive therapy.
Asymptomatic patients are entered into an immediate
treatment strategy. It is anticipated that the results
from this study will help deﬁne the most appropriate
time to initiate treatment of acute hepatitis C within
various subpopulations.
2. What type of IFN should be administered? Mono-
therapy studies with PEG-IFN alfa-2b have yielded
SVR rates similar to those reported with conventional
IFN alfa. With its once-weekly administration sche-
dule, PEG-IFN alfa-2b or alfa-2a may ultimately
become the standard of care in acute hepatitis C treat-
ment, though a head-to-head comparison with con-
ventional IFN would be required to conﬁrm
equivalence.
3. What is the optimal dosage of PEG-IFN alfa-2b? In
the studies of Calleri [52] and De Rosa [51], patients
received PEG-IFN alfa-2b doses ranging from 1.06
to 1.66 lg/kg/wk. Improved SVR rates were associ-
ated with PEG-IFN alfa-2 b doses >1.2 lg/kg/wk
[52] or >1.33 lg/kg/wk [51]. These data suggest that
the recommended 1.5 lg/kg/wk dose of PEG-IFN
alfa-2b should be used when treating patients with
acute disease.
4. What is the optimal treatment duration? At present,
the optimal duration of PEG-IFN monotherapy
seems to be 24 weeks; however, a 12-week course is
also eﬀective in patients treated with a full dosage
of PEG-IFN who attain undetectable HCV RNA at
week 4. A large, ongoing, randomised, multicentre
trial in Italy is investigating the eﬃcacy of shortened
treatment duration (12 versus 24 weeks). In this
study, all patients with diagnoses of acute hepatitis
C undergo a 12-week observation period followed
by repeat testing of HCV RNA levels; those with
detectable HCV RNA are then randomized to receive
PEG-IFN alfa-2b (1.5 lg/kg/wk) for 12 or 24 weeks.
This study also includes a third treatment arm con-
sisting of combination therapy with PEG-IFN alfa
plus ribavirin (>10.6 mg/kg/day) administered over
a 12-week period.
5. Which parameters can be used to predict treatment out-
come? Diﬀerent baseline parameters, such as gender,
age, mode of infection, baseline viral load and HCV
genotype, have been analysed by several investigators
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come [15,49,50,52]. Two studies, however, showpoorer
virological response in genotype 1 patients than in non-
genotype 1 patients, suggesting that genotypemay pre-
dict treatment outcome [16,17]. These observations
warrant further investigation; data from ongoing Ger-
man HEP-NET and Italian clinical trials should pro-
vide more insight into this topic.
6. How can diﬃcult-to-treat patients be identiﬁed and
serious side eﬀects be avoided? A crucial issue for the
success of treatment is patient adherence to therapy.
In diﬃcult-to-treat patients such as intravenous drug
abusers and patients with psychological disorders
who are at high risk for early treatment discontinua-
tion [67], indications for treatment must be discussed
on an individual patient level. A multidisciplinary
approach with eﬀective counseling can be used to
inform and motivate patients, thus increasing adher-
ence and averting serious side eﬀects.
7. Is PEG-IFN plus ribavirin combination therapy more
eﬀective than monotherapy? At present, there is no evi-
dence that the addition of ribavirin improves response
rates in patients with acute hepatitis C. It remains to
be established whether combination therapy would
permit a shortened treatment duration and whether
it can provide better results in immunocompromised
patients, such as those coinfected with HIV.7. Conclusions
In conclusion, treatment of acute hepatitis C with
IFN alfa oﬀers the opportunity to maximise the rates
of viral eradication with SVR in excess of 90%. How-
ever, the identiﬁcation of ideal candidates for treatment,
the optimal time for initiating therapy and the optimal
dose and duration of therapy require further investiga-
tion. Results of ongoing randomised trials will contrib-
ute to answering these questions. Surveillance
programs designed to monitor populations at high risk
represent the best approach for identifying patients with
acute hepatitis C. Such programs, together with a stan-
dardized approach to treatment, should increase the rec-
ognition of acute hepatitis C and the beneﬁts associated
with its eﬀective treatment.
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